Skip to main content
Top
Published in: Breast Cancer Research 1/2011

Open Access 01-02-2011 | Research article

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors

Authors: Jun J Mao, H Irene Su, Rui Feng, Michelle L Donelson, Richard Aplenc, Timothy R Rebbeck, Frank Stanczyk, Angela DeMichele

Published in: Breast Cancer Research | Issue 1/2011

Login to get access

Abstract

Introduction

Aromatase inhibitor-associated arthralgia (AIAA) is a common and often debilitating symptom in breast cancer survivors. Since joint symptoms have been related to estrogen deprivation through the menopausal transition, we hypothesized that genetic polymorphisms in CYP19A1, the final enzyme in estrogen synthesis, may be associated with the occurrence of AIAA.

Methods

We performed a cross-sectional study of postmenopausal women with stage 0 to III breast cancer receiving adjuvant aromatase inhibitor (AI) therapy. Patient-reported AIAA was the primary outcome. DNA was genotyped for candidate CYP19A1 polymorphisms. Serum estrogen levels were evaluated by radioimmunoassay. Multivariate analyses were performed to examine associations between AIAA and genetic variants controlling for possible confounders.

Results

Among 390 Caucasian participants, 50.8% reported AIAA. Women carrying at least one 8-repeat allele had lower odds of AIAA (adjusted odds ratio (AOR) 0.41, 95% confidence interval (CI) 0.21 to 0.79, P = 0.008) after adjusting for demographic and clinical covariates. Estradiol and estrone were detectable in 47% and 86% of subjects on AIs, respectively. Although these post-AI levels were associated with multiple genotypes, they were not associated with AIAA. In multivariate analyses, women with more recent transition into menopause (less than five years) were significantly more likely to report AIAA than those greater than ten years post-menopause (AOR 3.31, 95% CI 1.72 to 6.39, P < 0.001).

Conclusions

Functional polymorphism in CYP19A1 and time since menopause are associated with patient-reported AIAA, supporting the hypothesis that the host hormonal environment contributes to the pathophysiology of AAIA. Prospective investigation is needed to further delineate relationships between host genetics, changing estrogen levels and AIAA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chlebowski RT: Aromatase inhibitor-associated arthralgias. J Clin Oncol. 2009, 27: 4932-4934. 10.1200/JCO.2009.23.3270.CrossRefPubMed Chlebowski RT: Aromatase inhibitor-associated arthralgias. J Clin Oncol. 2009, 27: 4932-4934. 10.1200/JCO.2009.23.3270.CrossRefPubMed
2.
go back to reference Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P: Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev. 2008, 34: 275-282. 10.1016/j.ctrv.2007.10.004.CrossRefPubMed Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P: Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev. 2008, 34: 275-282. 10.1016/j.ctrv.2007.10.004.CrossRefPubMed
3.
go back to reference Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009, 115: 3631-3639. 10.1002/cncr.24419.CrossRefPubMedPubMedCentral Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009, 115: 3631-3639. 10.1002/cncr.24419.CrossRefPubMedPubMedCentral
4.
go back to reference Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007, 25: 3877-3883. 10.1200/JCO.2007.10.7573.CrossRefPubMed Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007, 25: 3877-3883. 10.1200/JCO.2007.10.7573.CrossRefPubMed
5.
go back to reference Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008, 26: 3147-3152. 10.1200/JCO.2007.15.4005.CrossRefPubMed Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008, 26: 3147-3152. 10.1200/JCO.2007.15.4005.CrossRefPubMed
6.
go back to reference Donnellan PP, Douglas SL, Cameron DA, Leonard RC: Aromatase inhibitors and arthralgia. J Clin Oncol. 2001, 19: 2767-PubMed Donnellan PP, Douglas SL, Cameron DA, Leonard RC: Aromatase inhibitors and arthralgia. J Clin Oncol. 2001, 19: 2767-PubMed
7.
go back to reference Felson DT, Cummings SR: Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005, 52: 2594-2598. 10.1002/art.21364.CrossRefPubMed Felson DT, Cummings SR: Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005, 52: 2594-2598. 10.1002/art.21364.CrossRefPubMed
8.
go back to reference Dugan SA, Powell LH, Kravitz HM, Everson Rose SA, Karavolos K, Luborsky J: Musculoskeletal pain and menopausal status. Clin J Pain. 2006, 22: 325-331. 10.1097/01.ajp.0000208249.07949.d5.CrossRefPubMed Dugan SA, Powell LH, Kravitz HM, Everson Rose SA, Karavolos K, Luborsky J: Musculoskeletal pain and menopausal status. Clin J Pain. 2006, 22: 325-331. 10.1097/01.ajp.0000208249.07949.d5.CrossRefPubMed
9.
go back to reference Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst. 2004, 96: 936-945. 10.1093/jnci/djh167.CrossRefPubMed Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst. 2004, 96: 936-945. 10.1093/jnci/djh167.CrossRefPubMed
10.
go back to reference Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ: A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 2000, 87: 204-210. 10.1002/1097-0215(20000715)87:2<204::AID-IJC8>3.0.CO;2-3.CrossRefPubMed Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ: A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 2000, 87: 204-210. 10.1002/1097-0215(20000715)87:2<204::AID-IJC8>3.0.CO;2-3.CrossRefPubMed
11.
go back to reference Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004, 13: 94-101. 10.1158/1055-9965.EPI-03-0026.CrossRefPubMed Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004, 13: 94-101. 10.1158/1055-9965.EPI-03-0026.CrossRefPubMed
12.
go back to reference Woods NF, Mitchell ES, Tao Y, Viernes HM, Stapleton PL, Farin FM: Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Menopause. 2006, 13: 902-910. 10.1097/01.gme.0000227058.70903.9f.CrossRefPubMed Woods NF, Mitchell ES, Tao Y, Viernes HM, Stapleton PL, Farin FM: Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Menopause. 2006, 13: 902-910. 10.1097/01.gme.0000227058.70903.9f.CrossRefPubMed
13.
go back to reference Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Greve J: Tolerance of adjuvant letrozole outside of clinical trials. Breast. 2008, 17: 376-381. 10.1016/j.breast.2008.02.006.CrossRefPubMed Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Greve J: Tolerance of adjuvant letrozole outside of clinical trials. Breast. 2008, 17: 376-381. 10.1016/j.breast.2008.02.006.CrossRefPubMed
14.
go back to reference Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, et al: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007, 67: 1893-1897. 10.1158/0008-5472.CAN-06-4123.CrossRefPubMed Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, et al: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007, 67: 1893-1897. 10.1158/0008-5472.CAN-06-4123.CrossRefPubMed
15.
go back to reference Kelberman D, Fife M, Rockman MV, Brull DJ, Woo P, Humphries SE: Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. Biochim Biophys Acta. 2004, 1688: 160-167.CrossRefPubMed Kelberman D, Fife M, Rockman MV, Brull DJ, Woo P, Humphries SE: Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. Biochim Biophys Acta. 2004, 1688: 160-167.CrossRefPubMed
16.
go back to reference Burstein HJ, Winer EP: Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007, 25: 3797-3799. 10.1200/JCO.2007.11.9529.CrossRefPubMed Burstein HJ, Winer EP: Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007, 25: 3797-3799. 10.1200/JCO.2007.11.9529.CrossRefPubMed
17.
go back to reference Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007, 25: 486-492. 10.1200/JCO.2006.08.8617.CrossRefPubMed Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007, 25: 486-492. 10.1200/JCO.2006.08.8617.CrossRefPubMed
18.
go back to reference Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007, 369: 559-570. 10.1016/S0140-6736(07)60200-1.CrossRefPubMed Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007, 369: 559-570. 10.1016/S0140-6736(07)60200-1.CrossRefPubMed
19.
go back to reference Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005, 97: 1262-1271. 10.1093/jnci/dji250.CrossRefPubMed Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005, 97: 1262-1271. 10.1093/jnci/dji250.CrossRefPubMed
20.
go back to reference Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016/S0140-6736(05)74803-0.CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016/S0140-6736(05)74803-0.CrossRefPubMed
21.
go back to reference Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006, 7: 903-909. 10.1016/S1470-2045(06)70910-X.CrossRefPubMed Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006, 7: 903-909. 10.1016/S1470-2045(06)70910-X.CrossRefPubMed
22.
go back to reference Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009, 101: 1624-1632. 10.1093/jnci/djp386.CrossRefPubMedPubMedCentral Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D: Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009, 101: 1624-1632. 10.1093/jnci/djp386.CrossRefPubMedPubMedCentral
23.
go back to reference Neben-Wittich MA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC: Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase iii trial of mometasone cream versus placebo during breast radiotherapy: The North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2010 Neben-Wittich MA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC: Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase iii trial of mometasone cream versus placebo during breast radiotherapy: The North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2010
24.
go back to reference Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004, 291: 2720-2726. 10.1001/jama.291.22.2720.CrossRefPubMed Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004, 291: 2720-2726. 10.1001/jama.291.22.2720.CrossRefPubMed
25.
go back to reference Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM: Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005, 65: 11071-11082. 10.1158/0008-5472.CAN-05-1218.CrossRefPubMed Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM: Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005, 65: 11071-11082. 10.1158/0008-5472.CAN-05-1218.CrossRefPubMed
26.
go back to reference Stanczyk FZ, Clarke NJ: Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 2010, 121: 491-495. 10.1016/j.jsbmb.2010.05.001.CrossRefPubMed Stanczyk FZ, Clarke NJ: Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 2010, 121: 491-495. 10.1016/j.jsbmb.2010.05.001.CrossRefPubMed
27.
go back to reference Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM: Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010, 70: 3278-3286. 10.1158/0008-5472.CAN-09-3024.CrossRefPubMedPubMedCentral Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM: Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010, 70: 3278-3286. 10.1158/0008-5472.CAN-09-3024.CrossRefPubMedPubMedCentral
28.
go back to reference Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008, 26: 1671-1676. 10.1200/JCO.2007.13.9279.CrossRefPubMed Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008, 26: 1671-1676. 10.1200/JCO.2007.13.9279.CrossRefPubMed
29.
go back to reference Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology. 2003, 21: 602-606. 10.1200/JCO.2003.07.071.CrossRefPubMed Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology. 2003, 21: 602-606. 10.1200/JCO.2003.07.071.CrossRefPubMed
30.
go back to reference Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010, 28: 4120-4128. 10.1200/JCO.2009.25.9655.CrossRefPubMedPubMedCentral Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010, 28: 4120-4128. 10.1200/JCO.2009.25.9655.CrossRefPubMedPubMedCentral
Metadata
Title
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
Authors
Jun J Mao
H Irene Su
Rui Feng
Michelle L Donelson
Richard Aplenc
Timothy R Rebbeck
Frank Stanczyk
Angela DeMichele
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2813

Other articles of this Issue 1/2011

Breast Cancer Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine